NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
Houston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma, showing a 48.9% six-month progression-free survival rate compared with a 20% historical benchmark.The result was nearly 2.5 times the historical benchmark and was statistically significant at p=0.0047.The study enrolled patients with advanced recurrent Grade III or Grade IV glioma...
Read releases like this the second they cross the wire.
1400+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 72-hour free trial, no card required.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.
PPN Source →